Autophagy regulates the function of myeloid-derived suppressor cells in tumor-induced immunosuppression

Authors

DOI:

https://doi.org/10.12923/cipms-2026-0021

Keywords:

autophagy, myeloid-derived suppressor cells (MDSCs), tumor microenvironment, immune suppression, immunotherapy, T-cell proliferation, tumor growth

Abstract

Tumor-infiltrating MDSCs were isolated from syngeneic C57BL/6 mouse models bearing B16-F10 melanoma or EO771 breast carcinoma tumors. Immunofluorescence staining of LC3B and western blotting of p62/SQSTM1 were used to assess autophagic activity. T-cell suppression by MDSCs was evaluated using co-culture assays, including assessment of T-cell proliferation by CFSE dilution and T-cell cytokine production by ELISA. Pharmacological inhibition of autophagy was performed using chloroquine, whereas genetic inhibition was achieved by knockdown of Atg5 using CRISPR-Cas9. Tumor growth and immune-cell infiltration were assessed in vivo following autophagy inhibition. MDSCs from tumor-bearing mice showed markedly higher autophagic activity than MDSCs from controls, with LC3B puncta and p62 levels increased 2.4-fold (p < 0.001). In co-culture, MDSCs inhibited T-cell proliferation by 55%, and this effect was partially reversed by autophagy inhibition. ELISA results indicated that IL-10, TGF-β, and IL-6 secretion by tumor-derived MDSCs was increased 1.5-fold and was significantly reduced by autophagy inhibition (p < 0.01). In vivo chloroquine treatment reduced tumor volume by 32% (p < 0.05) and increased CD8 + T-cell infiltration by 3.4-fold. Autophagy plays an important role in maintaining the immunosuppressive activity of MDSCs in the tumor microenvironment. Inhibition of autophagy reduces MDSC-mediated immunosuppression, restores T-cell activity, and inhibits tumor progression. These findings suggest that autophagy may represent a promising target for cancer immunotherapy.

References

1. Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, et al. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun Signal. 2020;18(1):59. doi:10.1186/s12964-020-0530-4.

2. Chouaib S, Kieda C, Benlalam H, Noman MZ, Mami-Chouaib F, Rüegg C. Endothelial cells as key determinants of the tumor microenvironment: interaction with tumor cells, extracellular matrix and immune killer cells. Crit Rev Immunol. 2010;30(6):529-45. doi:10.1615/CritRevImmunol.v30.i6.30.

3. Weiss F, Lauffenburger D, Friedl P. Towards targeting of shared mechanisms of cancer metastasis and therapy resistance. Nat Rev Cancer. 2022;22(3):157-73. doi:10.1038/s41568-021-00427-0.

4. Peña-Romero AC, Orenes-Piñero E. Dual effect of immune cells within tumour microenvironment: pro- and anti-tumour effects and their triggers. Cancers (Basel). 2022;14(7):1681. doi:10.3390/cancers14071681.

5. Kahya HFH, Mahmood MT. The relationship between stress and immune function: a review article. Commagene J Biol. 2025;9(1):112-22. doi:10.31594/commagene.1641548.

6. Lucchetti D, Ricciardi Tenore C, Colella F, Sgambato A. Extracellular vesicles and cancer: a focus on metabolism, cytokines, and immunity. Cancers (Basel). 2020;12(1):171. doi:10.3390/cancers12010171.

7. Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807-21. doi:10.1038/s41423-020-0488-6.

8. Tucci M, Passarelli A, Mannavola F, Felici C, Stucci LS, Cives M, et al. Immune system evasion as hallmark of melanoma progression: the role of dendritic cells. Front Oncol. 2019;9:1148. doi:10.3389/fonc.2019.01148.

9. Bhardwaj V, Ansell SM. Modulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies. Front Cell Dev Biol. 2023;11:1129343. doi:10.3389/fcell.2023.1129343.

10. Arner EN, Rathmell JC. Metabolic programming and immune suppression in the tumor microenvironment. Cancer Cell. 2023;41(3):421-33. doi:10.1016/j.ccell.2023.01.009.

11. Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368(6487). doi:10.1126/science.aaw5473.

12. Tamura R, Morimoto Y, Sato M, Kuranari Y, Oishi Y, Kosugi K, et al. Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas. J Neurooncol. 2020;146(2):265-73. doi:10.1007/s11060-019-03388-5.

13. Cui B, Lin H, Yu J, Yu J, Hu Z. Autophagy and the immune response. Adv Exp Med Biol. 2019;1206:595-634. doi:10.1007/ 978-981-15-0602-4_27.

14. Cadwell K. Crosstalk between autophagy and inflammatory signalling pathways: balancing defence and homeostasis. Nat Rev Immunol. 2016;16(11):661-75. doi:10.1038/nri.2016.100.

15. Germic N, Frangez Z, Yousefi S, Simon HU. Regulation of the innate immune system by autophagy: monocytes, macrophages, dendritic cells and antigen presentation. Cell Death Differ. 2019;26(4):715-27. doi:10.1038/s41418-019-0297-6.

16. Harris J. Autophagy and cytokines. Cytokine. 2011;56(2):140-4. doi:10.1016/j.cyto.2011.08.022.

17. Bronietzki AW, Schuster M, Schmitz I. Autophagy in T-cell development, activation and differentiation. Immunol Cell Biol. 2015;93(1):25-34. doi:10.1038/icb.2014.81.

18. Dowling SD, Macian F. Autophagy and T cell metabolism. Cancer Lett. 2018;419:20-6. doi:10.1016/j.canlet.2018.01.033.

19. Di Leo L, Bodemeyer V, De Zio D. The complex role of autophagy in melanoma evolution: new perspectives from mouse models. Front Oncol. 2020;9:1506. doi:10.3389/fonc.2019.01506.

20. De Spiegeleer A, Kahya H, Crombez L, Descamps A, Rössler R, Kressig RW, et al. Potential role of statins in treatment of acute sarcopenia. Med Hypotheses. 2023;177:111111. doi:10.1016/j.mehy.2023.111111.

21. Wang H, Sun P, Yuan X, Xu Z, Jiang X, Xiao M, et al. Autophagy in tumor immune escape and immunotherapy. Mol Cancer. 2025;24(1):85. doi:10.1186/s12943-025-02277-y.

22. Dong G, Si C, Zhang Q, Yan F, Li C, Zhang H, et al. Autophagy regulates accumulation and functional activity of granulocytic myeloid-derived suppressor cells via STAT3 signaling in endotoxin shock. Biochimica et biophysica acta Molecular basis of disease. 2017;1863(11):2796-807.doi: 10.1016/j.bbadis.2017.08.005

23. Jin S, Yang Z, Hao X, Tang W, Ma W, Zong H. Roles of HMGB1 in regulating myeloid-derived suppressor cells in the tumor microenvironment. Biomark Res. 2020;8(1):21. doi:10.1186/s40364-020-00201-8.

24. Zhang W, Li X, Jiang M, Ji C, Chen G, Zhang Q, et al. SOCS3 deficiency-dependent autophagy repression promotes the survival of early-stage myeloid-derived suppressor cells in breast cancer by activating the Wnt/mTOR pathway. J Leukoc Biol. 2023;113(5):445-60. doi:10.1093/jleuko/qiad020.

25. Levy JMM, Towers CG, Thorburn A. Targeting autophagy in cancer. Nat Rev Cancer. 2017;17(9):528-42. doi:10.1038/nrc.2017.53.

26. Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. 2017;5(1):3-8. doi:10.1158/2326-6066.CIR-16-0297.

27. Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J Clin Invest. 2015;125(9):3356-64. doi:10.1172/JCI80005.

28. Yamamoto K, Venida A, Yano J, Biancur DE, Kakiuchi M, Gupta S, et al. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I. Nature. 2020;581(7806):100-5. doi:10.1038/s41586-020-2229-5.

29. Hinshaw DC, Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557-66. doi:10.1158/0008-5472.CAN-18-3962.

30. Zhao Y, Du J, Shen X. Targeting myeloid-derived suppressor cells in tumor immunotherapy: current, future and beyond. Front Immunol. 2023;14:1157537. doi:10.3389/fimmu.2023.1157537.

31. Ou Y, Wei H, Peng C, Li J, Wei K, Zhan C, et al. Overcoming MDSC-mediated immunosuppression in hepatocellular carcinoma: from mechanisms to novel immunotherapeutic approaches. Cancers (Basel). 2026;18(6):980. doi:10.3390/cancers18060980.

Downloads

Published

2026-09-30

How to Cite

Kahya, H. F. H., Faris, R. K., & Mahmood, M. T. (2026). Autophagy regulates the function of myeloid-derived suppressor cells in tumor-induced immunosuppression. Current Issues in Pharmacy and Medical Sciences, 39(3), 133-140. https://doi.org/10.12923/cipms-2026-0021

Similar Articles

1-10 of 715

You may also start an advanced similarity search for this article.